MET and non-small cell lung carcinoma: Herein, we present a case of NSCLC patient harboring acquired MET amplification with a low GCN level (GCN = 3) after EGFR-TKI resistance achieving substantial response to savolitinib + osimertinib combination, hence resulting in progression-free survival (PFS) time reached of 7 months.